RKVTF (Rakovina Therapeutics) Short Interest


RKVTF Rakovina Therapeutics Inc RKVTF
34 GF Score
Price $0.09
! 1 Warning Sign
View Full Analysis

What is Rakovina Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RKVTF vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Rakovina Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rakovina Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's Short Interest falls into.


RKVTF
34GF Score
Rakovina Therapeutics Inc RKVTF
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rakovina Therapeutics Business Description

Other Exchanges 7JO0:GermanyRKV:Canada
Address 999 West Broadway, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a greater pace. The company has established a pipeline of distinctive DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Its drug development pipeline consists of candidates like kt-5000AI, kt-2000AI, and kt-3283, targeting solid tumours and PARP-resistant adult and childhood cancers.
34GF Score

Get the complete analysis for RKVTF

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price